ABOS
NASDAQ · Biotechnology
Acumen Pharmaceuticals Inc
$2.40
+0.15 (+6.67%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 32.13M | 32.40M | 26.28M |
| Net Income | 3.79M | 3.97M | 2.79M |
| EPS | — | — | — |
| Profit Margin | 11.8% | 12.2% | 10.6% |
| Rev Growth | +20.9% | +8.5% | +2.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 32.08M | 34.90M | 32.16M |
| Total Equity | 88.26M | 100.56M | 90.94M |
| D/E Ratio | 0.36 | 0.35 | 0.35 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 5.50M | 6.39M | 4.32M |
| Free Cash Flow | 1.86M | 2.43M | 2.61M |